@article{b4ef6fad683f43b7a0680524757c80dd,
title = "Colorectal cancer in 2014: Progress in defining first-line and maintenance therapies",
abstract = "The results of several clinical trials in metastatic colorectal cancer presented in 2014 will influence clinical practice. These findings include definitive data from phase III trials comparing bevacizumab and cetuximab-based therapy in the first-line, studies elucidating the value of maintenance therapy after induction treatment, and data on new agents in this disease.",
author = "Hubbard, {Joleen M.} and Axel Grothey",
note = "Funding Information: Research funding for J.M.H. was provided by Boston Biomedicals, Genentech and, PRISM. The Mayo Clinic Foundation received honoraria for consulting by J.M.H. from Bayer. Research funding for A.G. was provided by Bayer, Eisai/Morphotek, Eli–Lilly, Genentech, Pfizer, and Sanofi. A.G. received honoraria for consulting from Amgen, Bayer, Boston Biomedicals, Bristol–Myers Squibb, Eli-Lilly, Genentech/Roche, and Sanofi. Publisher Copyright: {\textcopyright} 2015 Macmillan Publishers Limited. All rights reserved.",
year = "2015",
month = feb,
day = "17",
doi = "10.1038/nrclinonc.2014.233",
language = "English (US)",
volume = "12",
pages = "73--74",
journal = "Nature Reviews Clinical Oncology",
issn = "1759-4774",
publisher = "Nature Publishing Group",
number = "2",
}